• Monday, August 30, 2021 @ 12:00 am

Strong H1 2021 results boosted by Cresemba increasing FY 2021 guidance.

Emerging cancer pipeline is rapidly progressing with 5 trials ongoing for derazantinib and lisavanbulin with many readouts. Zevtera “ERADICATE” data key to enter lucrative US market.

Key catalysts include:

  • Interim results “FIDES-02” trial derazantinib in urothelial cancer (H2 2021)
  • Lisavanbulin interim results phase II trial in brain cancer (H2 2021)
  • Complete enrollment phase III “ERADICATE” trial Zevtera in bacteremia (H2 2021)

To the full report

You may also be interested in